Article

Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients

Psychiatry Dept, University of Arkansas for Medical Sciences, Slot 843, 4301 W Markham St, Little Rock, AR 72205, USA.
Drug and alcohol dependence (Impact Factor: 3.28). 01/2011; 113(2-3):184-91. DOI: 10.1016/j.drugalcdep.2010.07.022
Source: PubMed

ABSTRACT This study examined the dose-related efficacy of disulfiram for treating cocaine dependence in methadone-stabilized cocaine dependent participants.
One hundred and sixty-one cocaine- and opioid-dependent volunteers were entered into a 14-week, double blind, randomized, placebo-controlled clinical trial at two sites.
Participants were stabilized on methadone during weeks 1-2 and received disulfiram at 0, 62.5, 125 or 250 mg/day during weeks 3-14. All participants also received weekly cognitive behavioral therapy. Thrice-weekly urine samples and weekly self-reported drug use assessments were obtained.
Baseline subject characteristics, retention and drug use did not differ across groups. Outcome analyses were performed on those who participated beyond week 2. Opioid-positive urine samples and self-reported opioid use did not differ by treatment group. The prevalence of alcohol use was low prior to and during the trial and did not differ by treatment group. Cocaine-positive urines increased over time in the 62.5 and 125 mg disulfiram groups and decreased over time in the 250 mg disulfiram and placebo groups (p < 0.0001). Self-reported cocaine use increased in the 125 mg disulfiram group relative to the other three treatment groups (p = 0.04).
Disulfiram may be contraindicated for cocaine dependence at doses <250 mg/day. Whether disulfiram at higher doses is efficacious in reducing cocaine use in dually cocaine and opioid dependent individuals needs to be determined.

Download full-text

Full-text

Available from: Michael J Mancino, Jul 29, 2015
0 Followers
 · 
171 Views
  • Source
    • "Inhibition of dopamine b-hydroxylase (DBH), a catecholamine biosynthetic enzyme that is required for NE production, reduces transmission at all NE receptors simultaneously. Disulfiram (Antabuse), which inhibits DBH by copper chelation, has shown promise in the clinic as a treatment for cocaine dependence (Carroll et al, 2004; Gaval-Cruz and Weinshenker, 2009; Oliveto et al, 2011), although disulfiram's lack of specificity, hepatotoxicity, and low tolerability limit its widespread and effective use (Gaval-Cruz and Weinshenker, 2009; Schroeder et al, 2010). Nepicastat is direct, competitive inhibitor of DBH "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although norepinephrine (NE) does not typically modulate cocaine self-administration under traditional schedules of reinforcement, it is required for different inducers of the reinstatement of cocaine-seeking behavior via activation of multiple adrenergic receptor subtypes. We predicted that blockade of NE synthesis would attenuate all known modalities of reinstatement, and showed previously that the selective dopamine β-hydroxylase (DBH) inhibitor, nepicastat, had no effect on either maintenance of operant cocaine self-administration maintained on a fixed-ratio 1 schedule or reinstatement of food seeking, but did abolish cocaine-primed reinstatement (Schroeder et al., 2010). In the present series of studies, we first evaluated the dose-dependent effect of nepicastat (5, 50, or 100 mg/kg) on novelty-induced locomotor activity, and found that it blunted exploration only at the highest dose. Next, we assessed the ability of nepicastat (50 mg/kg) to reduce breakpoint responding for cocaine on a progressive ratio schedule and reinstatement induced by drug-associated cues and stress. We found that nepicastat significantly lowered the breakpoint for cocaine, but not for regular chow or sucrose, and attenuated cue-, footshock-, and yohimbine-induced reinstatement. Combined, these results indicate that nepicastat can reduce the reinforcing properties of cocaine under a stringent schedule and can attenuate relapse-like behavior produced by cocaine, formerly cocaine-paired cues, and physiological and pharmacological stressors. Thus, nepicastat is one of those rare compounds that can reduce reinforced cocaine seeking as well as all three reinstatement modalities, while sparing exploratory behavior and natural reward seeking, making it a promising pharmacotherapy for cocaine addiction.Neuropsychopharmacology accepted article preview online, 3 January 2013; doi:10.1038/npp.2012.267.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 01/2013; 38(6). DOI:10.1038/npp.2012.267 · 7.83 Impact Factor
  • Source
    • "By contrast, significant reductions in cocaine use have been found in two studies of disulfiram (250 mg/day) combined with methadone maintenance (Petrakis et al., 2000) (Ib) and buprenorphine maintenance (George et al., 2000) (Ib). A more recent double-blind , placebo-controlled RCT of disulfiram for treatment of cocaine abuse in methadone-stabilised patients found increasing cocaine use in patients treated with low-dose disulfiram (62.5 mg or 125 mg daily) and decreasing cocaine use only in patients given high-dose disulfiram (250 mg; Oliveto et al., 2011) (Ib). Two studies adding tiagabine to methadone maintenance treatment (González et al., 2003, 2007) (Ib) have found significant reductions in cocaine use at 12-week follow-up. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.
    Journal of Psychopharmacology 05/2012; 26(7):899-952. DOI:10.1177/0269881112444324 · 2.81 Impact Factor
  • Source
    • "Patients in the study by Pettinati et al. were also dependent on alcohol, and only 1/3 took >80% of their disulfiram doses, which likely contributed to the lack of efficacy for disulfiram in this study. Interestingly, results from a recent large clinical trial suggest that low doses of disulfiram increase cocaine use (Oliveto et al., 2011). We have also observed striking differences in the effects of disulfiram of cocaine-mediated effects based on dose; low doses increase, and high doses decrease, the reinforcing effects of cocaine in humans (Haile et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Much effort has been devoted to research focused on pharmacotherapies for cocaine dependence yet there are no FDA-approved medications for this brain disease. Preclinical models have been essential to defining the central and peripheral effects produced by cocaine. Recent evidence suggests that cocaine exerts its reinforcing effects by acting on multiple neurotransmitter systems within mesocorticolimibic circuitry. Imaging studies in cocaine-dependent individuals have identified deficiencies in dopaminergic signaling primarily localized to corticolimbic areas. In addition to dysregulated striatal dopamine, norepinephrine and glutamate are also altered in cocaine dependence. In this review, we present these brain abnormalities as therapeutic targets for the treatment of cocaine dependence. We then survey promising medications that exert their therapeutic effects by presumably ameliorating these brain deficiencies. Correcting neurochemical deficits in cocaine-dependent individuals improves memory and impulse control, and reduces drug craving that may decrease cocaine use. We hypothesize that using medications aimed at reversing known neurochemical imbalances is likely to be more productive than current approaches. This view is also consistent with treatment paradigms used in neuropsychiatry and general medicine.
    Pharmacology [?] Therapeutics 01/2012; 134(2):260-77. DOI:10.1016/j.pharmthera.2012.01.010 · 7.75 Impact Factor
Show more